Cargando…

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

BACKGROUND: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19. METHODS: This randomised, controlled, open-label, platform trial (R...

Descripción completa

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121538/ https://www.ncbi.nlm.nih.gov/pubmed/34000257 http://dx.doi.org/10.1016/S0140-6736(21)00897-7

Ejemplares similares

Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Colchicine in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2021)

Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Lopinavir–ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2020)

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2022)

Use of covid-19 convalescent plasma to treat patients admitted to hospital for covid-19 with or without underlying immunodeficiency: open label, randomised clinical trial
por: Lacombe, Karine, et al.
Publicado: (2023)

Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publicado: (2022)

Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
por: Bégin, Philippe, et al.
Publicado: (2021)

Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial
por: Sekine, Leo, et al.
Publicado: (2022)

Author Correction: Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial
por: Bégin, Philippe, et al.
Publicado: (2022)

Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Publicado: (2023)

Efficacy of convalescent plasma therapy for COVID-19 in Japan: An open-label, randomized, controlled trial
por: Saito, Sho, et al.
Publicado: (2023)

Convalescent plasma for treatment of COVID-19: study protocol for an open randomised controlled trial in Sweden
por: Dillner, Joakim, et al.
Publicado: (2021)

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
Publicado: (2020)

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
por: Agarwal, Anup, et al.
Publicado: (2020)

A phase 2 single center open label randomised control trial for convalescent plasma therapy in patients with severe COVID-19
por: Ray, Yogiraj, et al.
Publicado: (2022)

Convalescent Plasma Therapy in Critically Ill COVID-19 Patients: An Open Label Trial
por: Khamis, Faryal, et al.
Publicado: (2021)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19 (COVIC-19): protocol for a randomised, open-label trial
por: Desmarets, Maxime, et al.
Publicado: (2023)

Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial
por: Hamilton, F.W., et al.
Publicado: (2021)

Efficacy of convalescent plasma therapy in the patient with COVID-19: a randomised control trial (COPLA-II trial)
por: Bajpai, Meenu, et al.
Publicado: (2022)

Therapeutic versus prophylactic anticoagulation for patients admitted to hospital with COVID-19 and elevated D-dimer concentration (ACTION): an open-label, multicentre, randomised, controlled trial
por: Lopes, Renato D, et al.
Publicado: (2021)

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial
por: Cohen, Jordana B, et al.
Publicado: (2021)

Evaluation of convalescent plasma versus standard of care for the treatment of COVID-19 in hospitalized patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
por: Diago-Sempere, Elena, et al.
Publicado: (2021)

A randomized placebo-controlled trial of convalescent plasma for adults hospitalized with COVID-19 pneumonia
por: Thorlacius-Ussing, Louise, et al.
Publicado: (2022)

Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden
por: Holm, Karin, et al.
Publicado: (2021)

Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial
por: Bégin, Philippe, et al.
Publicado: (2021)

Convalescent plasma therapy and mortality in COVID-19 patients admitted to the ICU: a prospective observational study
por: Hatzl, Stefan, et al.
Publicado: (2021)

Heterogeneity in COVID‐19 Convalescent Plasma Clinical Trials
por: Müller‐Olling, Mirco, et al.
Publicado: (2021)

COVID-19 convalescent plasma
por: Tobian, Aaron A. R., et al.
Publicado: (2022)

Convalescent plasma to treat critically ill patients with COVID-19: framing the need for randomised clinical trials
por: Shankar-Hari, Manu, et al.
Publicado: (2020)

Neutralizing COVID-19 Convalescent Plasma in Adults Hospitalized With COVID-19: A Blinded, Randomized, Placebo-Controlled Trial
por: Self, Wesley H., et al.
Publicado: (2022)

Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
por: Hung, Ivan Fan-Ngai, et al.
Publicado: (2020)

Report of the first seven agents in the I-SPY COVID trial: a phase 2, open label, adaptive platform randomised controlled trial
Publicado: (2023)

Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk
por: Hayward, Gail, et al.
Publicado: (2021)

Convalescent Plasma Efficacy in Life-Threatening COVID-19 Patients Admitted to the ICU: A Retrospective Cohort Study
por: Abuzakouk, Mohamed, et al.
Publicado: (2021)

Convalescent plasma to treat COVID-19
por: Bloch, Evan M.
Publicado: (2020)

Convalescent plasma for patients with COVID-19
por: Zeng, Furong, et al.
Publicado: (2020)

Convalescent plasma for COVID-19 considerations
por: Adiwinata Pawitan, Jeanne
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqn9dg2c6ocbsfvrn64hbabgim